ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO0545

Management of Serum Phosphorus (sP) Over One-Year Follow-Up in Peritoneal Dialysis (PD) Patients Prescribed Sucroferric Oxyhydroxide (SO) as Part of Routine Care

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical

Authors

  • Kalantar-Zadeh, Kamyar, University of California Irvine, School of Medicine, Orange, California, United States
  • Ficociello, Linda, Fresenius Medical Care Global Medical Office, Waltham, Massachusetts, United States
  • Zhou, Meijiao, Fresenius Medical Care Global Medical Office, Waltham, Massachusetts, United States
  • Parameswaran, Vidhya, Fresenius Medical Care Global Medical Office, Waltham, Massachusetts, United States
  • Mullon, Claudy, Fresenius Medical Care Global Medical Office, Waltham, Massachusetts, United States
  • Anger, Michael S., Fresenius Medical Care Global Medical Office, Waltham, Massachusetts, United States
Background

Clinical and observational studies have shown the effectiveness of SO in controlling sP in PD patients (pts). A real-world retrospective analysis in a PD cohort prescribed SO for 6 months demonstrated an association between SO prescription and lower sP. The current analysis examines the changes in sP and PB pill burden over a one-year period in PD patients converting to SO.

Methods

We included adult Fresenius Kidney Care (FKC) PD pts (n=260) first prescribed SO monotherapy during 5/2018- 5/2019 who had sP measured 91 days before SO prescription (baseline; BL). Comparisons were made between BL and the four consecutive 91-day intervals of SO treatment (Q1-Q4). Means of PB pill burden and lab measures were calculated using mixed effects linear regression.

Results

At BL, mean age was 54 years old with PD vintage 18 months, 37% pts had no PB prescriptions recorded and the remaining pts were prescribed sevelamer (36%), calcium acetate (33%), lanthanum (1%), ferric citrate (13%), switched between PB (10%), or >1 PB recorded (6%). After switching to SO, % of pts achieving sP<= 5.5 mg/dL increased from 32.7% at BL to 46.9%- 53.8% during SO FU, % of pts achieving sP<= 4.5 mg/dL increased by 153% from BL to Q4, along with fewer PB pills per day (7.6 at BL vs 4.4-5.2 at FU).

Conclusion

During a one-year observation period, PD pts prescribed SO as part of routine care during 2018-2019 had significant reductions in sP and PB pills/day and increases in % of pts with sP≤ 5.5 mg/mL or sP≤ 4.5 mg/mL, suggesting improved sP management with concurrent reduction in pill burden.

Funding

  • Commercial Support – Fresenius Medical Care Renal Therapies Group